Developer docs
API playgroundTry for free, no card

Search company profiles

Corcept Therapeutics

Full company profile

uuid0006wph

Namestring
Corcept Therapeutics
Legal namestring
Corcept Therapeutics Incorporated
Websiteurl
corcept.com
Company typeenum
Public
Founded yearint
1999
Descriptiontext

Corcept Therapeutics is a Menlo Park, California-based biopharmaceutical company founded in 1999 by Joseph K. Belanoff and Alan F. Schatzberg to develop small-molecule drugs that modulate cortisol activity at the glucocorticoid receptor (GR). The company has built a proprietary library of more than 1,000 selective glucocorticoid receptor antagonists (SGRAs) and runs 30+ ongoing clinical studies spanning endocrinology, oncology, metabolism, and neurology. Its two FDA-approved products are Korlym (mifepristone), the first treatment approved for hypercortisolism/Cushing's syndrome in 2012, and Lifyorli (relacorilant), the first selective GR antagonist approved for any oncology indication after FDA approval in March 2026 for platinum-resistant ovarian cancer in combination with nab-paclitaxel. The pipeline includes relacorilant (Cushing's syndrome NDA resubmitted June 2026 following a December 2025 Complete Response Letter), dazucorilant (Phase 2 ALS data showing an 87% reduction in death risk at two years, Phase 3 planned), and miricorilant (Phase 2 MONARCH in MASH).

The business is organized around specialty pharmaceutical commercialization: Corcept sells its approved drugs through specialty pharmacy partnerships (Onco360 was selected as the national pharmacy partner for Lifyorli) and supports prescribers and patients through the Corcept Cares Patient Advocate Program, medical affairs engagement, and educational platforms. Korlym prescriptions have nearly doubled year-over-year despite authorized generics now representing over 50% of prescriptions and driving a 13% year-over-year average per-tablet price decline. Revenue grew from $675 million in 2024 to $761 million in 2025, with Q1 2026 revenue of $164.9 million and management's 2026 guidance raised to $950 million-$1.05 billion reflecting transition from a single Cushing's syndrome franchise to a multi-product oncology and endocrinology portfolio. The company employs 400+ people and is publicly traded on NASDAQ under the ticker CORT with a market capitalization of approximately $7.45 billion as of late May 2026, up roughly 114% year-to-date following the Lifyorli approval.

Short descriptiontext

Corcept Therapeutics is a Menlo Park-based biopharmaceutical company that discovers and commercializes selective glucocorticoid receptor antagonists, with two FDA-approved drugs (Korlym for Cushing's syndrome, Lifyorli for platinum-resistant ovarian cancer) and a pipeline spanning endocrinology, oncology, metabolism, and neurology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cortisol modulation therapy, selective glucocorticoid receptor antagonists, hypercortisolism treatment, ovarian cancer therapeutics, endocrinology biopharmaceuticals
Industry1 code
PRIMARYHLAKADAN
Endocrine Hypertension & Neuroendocrine Disorders
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Endocrinology / Oncology Specialty Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales (Korlym and Lifyorli)
TypeOne Time License
Description

Corcept generates revenue primarily from the sale of two FDA-approved drugs: Korlym (mifepristone) for Cushing's syndrome, which was the first approved treatment for hypercortisolism (2012), and Lifyorli (relacorilant) for platinum-resistant ovarian cancer (FDA approved March 2026). Revenue is driven by prescription volume, with the company noting pricing pressures from authorized generics now accounting for over 50% of prescriptions causing a 13% year-over-year average price decline per tablet for Korlym. 2025 full-year revenue was $761 million (up 13% from $675 million in 2024). Q1 2026 revenue was $164.9 million.

fool.com
2Revenue from Cushing's Syndrome Franchise
TypeSubscription Recurring
Description

Strong prescriber growth with prescriptions nearly doubling year-over-year for Korlym, supported by record patient starts. Full-year 2026 guidance set at $950 million to $1.05 billion, reflecting transition from single-product Cushing's syndrome focus toward broader glucocorticoid receptor-targeted oncology and endocrine portfolio.

fool.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain
Pricing details1 tier
1Korlym (mifepristone) - prescription drug for Cushing's syndrome
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing subject to state-level prescriber disclosure requirements (Vermont, Colorado, Connecticut). Authorized generics now represent over 50% of prescriptions, causing ~13% average price decline per tablet year-over-year. No standard public list price available.

corcept.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Corcept Therapeutics discovers, develops, and commercializes FDA-approved drugs that regulate the effects of cortisol by modulating the glucocorticoid receptor (GR). The company sells two approved drugs: Korlym (mifepristone), the first FDA-approved treatment for hypercortisolism (Cushing's syndrome) approved in 2012, and Lifyorli (relacorilant), the first selective glucocorticoid receptor antagonist approved (March 2026) for platinum-resistant ovarian cancer in combination with nab-paclitaxel.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 35% reduction in risk of death (HR: 0.65; p=0.0004) and 30% reduction in risk of disease progression in platinum-resistant ovarian cancer with Lifyorli plus nab-paclitaxel vs nab-paclitaxel alone; median OS 16.0 months vs 11.9 months
+5 more records
Product overview1 text field

Corcept Therapeutics is a biopharmaceutical company focused on cortisol modulation therapy with two FDA-approved products and multiple clinical-stage candidates. The company's portfolio consists of Korlym (mifepristone), approved in 2012 as the first treatment for hypercortisolism (Cushing syndrome), and Lifyorli (relacorilant), approved in March 2026 as the first selective glucocorticoid receptor antagonist for platinum-resistant ovarian cancer. The company is pursuing additional indications for relacorilant in Cushing's syndrome, has dazucorilant in Phase 2 for ALS, and miricorilant in Phase 2 for MASH, with over 30 ongoing clinical studies across endocrinology, oncology, metabolism, and neurology.

Product and service2 records
1Korlym (mifepristone)
CategoryFDA-approved specialty pharmaceutical (endocrinology / hypercortisolism)
Description

FDA-approved treatment for hypercortisolism (Cushing's syndrome), the first approved treatment for this condition. Mifepristone is a glucocorticoid receptor antagonist that competitively and reversibly binds to the glucocorticoid receptor to modulate cortisol activity. Korlym is sold as 300 mg tablets and faces authorized-generic pricing pressure, with authorized generics now accounting for over 50% of prescriptions.

2Lifyorli (relacorilant)
CategoryFDA-approved specialty pharmaceutical (oncology / platinum-resistant ovarian cancer)
Description

FDA-approved selective glucocorticoid receptor antagonist (SGRA) approved in March 2026 in combination with nab-paclitaxel for treating adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. It is the first FDA-approved selective glucocorticoid receptor antagonist for oncology, included in NCCN Guidelines as a preferred regimen, and is distributed nationally through Onco360 specialty pharmacy.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-26
Description

Onco360, the largest independent oncology pharmacy in the United States, was selected as the national pharmacy partner for LIFYORLI (relacorilant). Onco360 provides specialized dispensing, clinical support, and patient services for oncology medications, enabling Corcept to reach patients with platinum-resistant ovarian cancer across the country.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major oncology player with PARP inhibitors (Talzenna) and broad ovarian cancer development programs; competes for platinum-resistant ovarian cancer share.

TypeDirect peer
Description

Clinical-stage endocrine-focused biotech developing paltusotine for acromegaly and Cushing's syndrome. Competes directly with Corcept's cortisol/glucocorticoid receptor franchise in hypercortisolism.

TypeEmerging player
Description

Private biotech developing SPI-62, a selective HSD-11β1 inhibitor targeting cortisol-driven diseases. Direct overlap with Corcept's Cushing's syndrome and cardiometabolic positioning.

TypeBroad incumbent
Description

Global specialty pharma with Signifor (pasireotide) approved for Cushing's disease. Competes with Korlym and relacorilant in the same Cushing's syndrome specialty channel.

TypeBroad incumbent
Description

Large pharma with historic presence in Cushing's disease via pasireotide co-development and broader oncology footprint relevant to platinum-resistant ovarian cancer.

TypeBroad incumbent
Description

Oncology incumbent with Lynparza in ovarian cancer and a broad development pipeline; competes for the same platinum-resistant ovarian cancer patients as Lifyorli.

TypeEmerging player
Description

Oncology company historically focused on ovarian cancer with Rubraca; provides a comparable commercial and clinical profile in the platinum-resistant ovarian cancer segment where Lifyorli launches.

TypeDirect peer
Description

Developer of Elahere (mirvetuximab soravtansine), an ADC approved for platinum-resistant ovarian cancer; competes head-to-head with Lifyorli + nab-paclitaxel in the same indication and patient population.

TypeBroad incumbent
Description

European specialty pharma with a rare endocrine and rare disease portfolio; comparable commercial model targeting endocrinology specialists for niche indications.

TypeEmerging player
Description

Mid-cap biotech with rare endocrine and cardiometabolic programs (e.g., acromegaly assets); comparable specialty commercial model and overlapping specialist prescriber base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Corcept Therapeutics

Endocrinology / Oncology Specialty Biopharmaceuticalscorcept.com

Corcept Therapeutics is a Menlo Park-based biopharmaceutical company that discovers and commercializes selective glucocorticoid receptor antagonists, with two FDA-approved drugs (Korlym for Cushing's syndrome, Lifyorli for platinum-resistant ovarian cancer) and a pipeline spanning endocrinology, oncology, metabolism, and neurology.

What Corcept Therapeutics does

Corcept Therapeutics is a Menlo Park, California-based biopharmaceutical company founded in 1999 by Joseph K. Belanoff and Alan F. Schatzberg to develop small-molecule drugs that modulate cortisol activity at the glucocorticoid receptor (GR). The company has built a proprietary library of more than 1,000 selective glucocorticoid receptor antagonists (SGRAs) and runs 30+ ongoing clinical studies spanning endocrinology, oncology, metabolism, and neurology. Its two FDA-approved products are Korlym (mifepristone), the first treatment approved for hypercortisolism/Cushing's syndrome in 2012, and Lifyorli (relacorilant), the first selective GR antagonist approved for any oncology indication after FDA approval in March 2026 for platinum-resistant ovarian cancer in combination with nab-paclitaxel. The pipeline includes relacorilant (Cushing's syndrome NDA resubmitted June 2026 following a December 2025 Complete Response Letter), dazucorilant (Phase 2 ALS data showing an 87% reduction in death risk at two years, Phase 3 planned), and miricorilant (Phase 2 MONARCH in MASH).

The business is organized around specialty pharmaceutical commercialization: Corcept sells its approved drugs through specialty pharmacy partnerships (Onco360 was selected as the national pharmacy partner for Lifyorli) and supports prescribers and patients through the Corcept Cares Patient Advocate Program, medical affairs engagement, and educational platforms. Korlym prescriptions have nearly doubled year-over-year despite authorized generics now representing over 50% of prescriptions and driving a 13% year-over-year average per-tablet price decline. Revenue grew from $675 million in 2024 to $761 million in 2025, with Q1 2026 revenue of $164.9 million and management's 2026 guidance raised to $950 million-$1.05 billion reflecting transition from a single Cushing's syndrome franchise to a multi-product oncology and endocrinology portfolio. The company employs 400+ people and is publicly traded on NASDAQ under the ticker CORT with a market capitalization of approximately $7.45 billion as of late May 2026, up roughly 114% year-to-date following the Lifyorli approval.

Corcept Therapeutics firmographics

Firmographics
Name
Corcept Therapeutics
Legal name
Corcept Therapeutics Incorporated
Website
https://corcept.com
Company type
Public
Founded year
1999
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Corcept Therapeutics is a Menlo Park-based biopharmaceutical company that discovers and commercializes selective glucocorticoid receptor antagonists, with two FDA-approved drugs (Korlym for Cushing's syndrome, Lifyorli for platinum-resistant ovarian cancer) and a pipeline spanning endocrinology, oncology, metabolism, and neurology.
Ownership category
akta.pro rank

Corcept Therapeutics industry classification

Industry
Product category
Endocrinology / Oncology Specialty Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKADAN
Endocrine Hypertension & Neuroendocrine Disorders

Keywords

  • Cortisol modulation therapy
  • Selective glucocorticoid receptor antagonists
  • Hypercortisolism treatment
  • Ovarian cancer therapeutics
  • Endocrinology biopharmaceuticals

Where Corcept Therapeutics is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Corcept Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain

Revenue model

  1. Product Sales (Korlym and Lifyorli): Corcept generates revenue primarily from the sale of two FDA-approved drugs: Korlym (mifepristone) for Cushing's syndrome, which was the first approved treatment for hypercortisolism (2012), and Lifyorli (relacorilant) for platinum-resistant ovarian cancer (FDA approved March 2026). Revenue is driven by prescription volume, with the company noting pricing pressures from authorized generics now accounting for over 50% of prescriptions causing a 13% year-over-year average price decline per tablet for Korlym. 2025 full-year revenue was $761 million (up 13% from $675 million in 2024). Q1 2026 revenue was $164.9 million.
  2. Revenue from Cushing's Syndrome Franchise: Strong prescriber growth with prescriptions nearly doubling year-over-year for Korlym, supported by record patient starts. Full-year 2026 guidance set at $950 million to $1.05 billion, reflecting transition from single-product Cushing's syndrome focus toward broader glucocorticoid receptor-targeted oncology and endocrine portfolio.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractKorlym (mifepristone) - prescription drug for Cushing's syndrome

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Corcept Therapeutics product offering

Product offering

Core offering

Corcept Therapeutics discovers, develops, and commercializes FDA-approved drugs that regulate the effects of cortisol by modulating the glucocorticoid receptor (GR). The company sells two approved drugs: Korlym (mifepristone), the first FDA-approved treatment for hypercortisolism (Cushing's syndrome) approved in 2012, and Lifyorli (relacorilant), the first selective glucocorticoid receptor antagonist approved (March 2026) for platinum-resistant ovarian cancer in combination with nab-paclitaxel.

Product overview

Corcept Therapeutics is a biopharmaceutical company focused on cortisol modulation therapy with two FDA-approved products and multiple clinical-stage candidates. The company's portfolio consists of Korlym (mifepristone), approved in 2012 as the first treatment for hypercortisolism (Cushing syndrome), and Lifyorli (relacorilant), approved in March 2026 as the first selective glucocorticoid receptor antagonist for platinum-resistant ovarian cancer. The company is pursuing additional indications for relacorilant in Cushing's syndrome, has dazucorilant in Phase 2 for ALS, and miricorilant in Phase 2 for MASH, with over 30 ongoing clinical studies across endocrinology, oncology, metabolism, and neurology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Korlym (mifepristone) FDA-approved treatment for hypercortisolism (Cushing's syndrome), the first approved treatment for this condition. Mifepristone is a glucocorticoid receptor antagonist that competitively and reversibly binds to the glucocorticoid receptor to modulate cortisol activity. Korlym is sold as 300 mg tablets and faces authorized-generic pricing pressure, with authorized generics now accounting for over 50% of prescriptions.
  • Lifyorli (relacorilant) FDA-approved selective glucocorticoid receptor antagonist (SGRA) approved in March 2026 in combination with nab-paclitaxel for treating adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. It is the first FDA-approved selective glucocorticoid receptor antagonist for oncology, included in NCCN Guidelines as a preferred regimen, and is distributed nationally through Onco360 specialty pharmacy.

Quantifiable outcome

  • 35% reduction in risk of death (HR: 0.65; p=0.0004) and 30% reduction in risk of disease progression in platinum-resistant ovarian cancer with Lifyorli plus nab-paclitaxel vs nab-paclitaxel alone; median OS 16.0 months vs 11.9 months
  • +5 more outcomes

Companies that use Corcept Therapeutics

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Corcept Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Corcept Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Onco360coreChannel Partner/ Reseller/ Distributor · 26 March 2026Onco360, the largest independent oncology pharmacy in the United States, was selected as the national pharmacy partner for LIFYORLI (relacorilant). Onco360 provides specialized dispensing, clinical support, and patient services for oncology medications, enabling Corcept to reach patients with platinum-resistant ovarian cancer across the country.

Scale indicators10 records

Recent moves6 records

Expansion highlights4 records

Corcept Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Major oncology player with PARP inhibitors (Talzenna) and broad ovarian cancer development programs; competes for platinum-resistant ovarian cancer share.
  • Ipsen: Global specialty pharma with Signifor (pasireotide) approved for Cushing's disease. Competes with Korlym and relacorilant in the same Cushing's syndrome specialty channel.
  • Novartis: Large pharma with historic presence in Cushing's disease via pasireotide co-development and broader oncology footprint relevant to platinum-resistant ovarian cancer.
  • AstraZeneca: Oncology incumbent with Lynparza in ovarian cancer and a broad development pipeline; competes for the same platinum-resistant ovarian cancer patients as Lifyorli.
  • Recordati: European specialty pharma with a rare endocrine and rare disease portfolio; comparable commercial model targeting endocrinology specialists for niche indications.

Direct peers

  • Crinetics Pharmaceuticals: Clinical-stage endocrine-focused biotech developing paltusotine for acromegaly and Cushing's syndrome. Competes directly with Corcept's cortisol/glucocorticoid receptor franchise in hypercortisolism.
  • ImmunoGen: Developer of Elahere (mirvetuximab soravtansine), an ADC approved for platinum-resistant ovarian cancer; competes head-to-head with Lifyorli + nab-paclitaxel in the same indication and patient population.

Emerging players

  • Sparrow Pharmaceuticals: Private biotech developing SPI-62, a selective HSD-11β1 inhibitor targeting cortisol-driven diseases. Direct overlap with Corcept's Cushing's syndrome and cardiometabolic positioning.
  • Clovis Oncology: Oncology company historically focused on ovarian cancer with Rubraca; provides a comparable commercial and clinical profile in the platinum-resistant ovarian cancer segment where Lifyorli launches.
  • BridgeBio Pharma: Mid-cap biotech with rare endocrine and cardiometabolic programs (e.g., acromegaly assets); comparable specialty commercial model and overlapping specialist prescriber base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Corcept Therapeutics social profiles

Digital presence

Corcept Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Corcept Therapeutics leadership team

Management profile

Number of profiles

Profiles17 records

Corcept Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Corcept Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corcept Therapeutics

What does Corcept Therapeutics do?

Corcept Therapeutics discovers, develops, and commercializes FDA-approved drugs that regulate the effects of cortisol by modulating the glucocorticoid receptor (GR). The company sells two approved drugs: Korlym (mifepristone), the first FDA-approved treatment for hypercortisolism (Cushing's syndrome) approved in 2012, and Lifyorli (relacorilant), the first selective glucocorticoid receptor antagonist approved (March 2026) for platinum-resistant ovarian cancer in combination with nab-paclitaxel.

Is Corcept Therapeutics a public or private company?

Corcept Therapeutics is a public company. It is classified as public and is currently operating.

When was Corcept Therapeutics founded?

Corcept Therapeutics was founded in 1999. It employs 501 to 1,000 people.

Where is Corcept Therapeutics based?

Corcept Therapeutics is headquartered in Redwood City, United States, in the North America region.

How does Corcept Therapeutics make money?

Two revenue lines are on record. Product Sales (Korlym and Lifyorli) is the primary driver. The others are revenue from Cushing's Syndrome Franchise.

Who are Corcept Therapeutics's main competitors?

Broad incumbents on record are Pfizer, Ipsen, Novartis, AstraZeneca and Recordati. Direct peers are Crinetics Pharmaceuticals and ImmunoGen. Emerging players are Sparrow Pharmaceuticals, Clovis Oncology and BridgeBio Pharma.

Does Corcept Therapeutics have an API?

No public API is recorded for Corcept Therapeutics.

What industry is Corcept Therapeutics in?

Corcept Therapeutics's product category is Endocrinology / Oncology Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAKADAN, Endocrine Hypertension & Neuroendocrine Disorders. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingCorcept Therapeutics Director James N. Wilson Reports Disposal of $726,677.9383 in Common SharesCorcept Therapeutics director James N. Wilson sold 10,000 common shares on Nov. 13, 2026, at prices ranging from $71.8011 to $74.28 per share. Following the sale, his indirect holdings totaled 1,044,543 shares through a family trust, with another 400,000 shares held through two annuity trusts.Simply Wall StHow Investors Are Reacting To Corcept Therapeutics Stock After Earnings BeatCorcept Therapeutics reported Q3 2026 net income of $126.78 million, up from $19.67 million a year earlier, with diluted EPS of $1.01 versus $0.16. The company reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion, citing alignment between profitability and top-line expectations.Simply Wall StCorcept Therapeutics (CORT) Shares Dropped, So What Is Driving Attention Now?Corcept Therapeutics reported Q3 net income of $126.78 million and EPS of $1.17, but its stock fell 39.5% over the past month. The company reaffirmed 2026 revenue guidance of $1.1–1.2 billion, while analysts see a fair value of $141, implying undervaluation.Defense WorldCorcept Therapeutics Incorporated (NASDAQ:CORT) Stock Now Rated “Moderate Buy” by Wall Street AnalystsCorcept Therapeutics received a consensus "Moderate Buy" rating from eight analysts, with an average price target of $139.50. The company reported Q3 EPS of $1.01, beating estimates, and revenue of $340.47 million, up 64% year-over-year. Insiders sold 382,536 shares in the last quarter.American Banking and Market NewsCorcept Therapeutics (NASDAQ:CORT) Insider Sells $1,082,327.75 in StockInsider Sean Maduck sold 13,159 Corcept Therapeutics shares on November 3rd at $82.25, reducing his stake by 56.97%. The company reported Q4 EPS of $1.01, beating estimates, with revenue up 64% year-over-year. Analysts have a consensus 'Moderate Buy' rating with a $139.50 target.American Banking and Market NewsCorcept Therapeutics Incorporated (NASDAQ:CORT) Stock Has Consensus Target Price of $139.50 According to BrokeragesCorcept Therapeutics shares opened at $72.77, with analysts giving a Moderate Buy consensus and a $139.50 price target. The company reported Q4 EPS of $1.01, beating estimates, and revenue of $340.47 million, up 64% year-over-year. Insiders sold 382,536 shares in the last three months.American Banking and Market NewsCorcept Therapeutics (NASDAQ:CORT) Stock Crosses Below Two Hundred Day Moving Average on Insider SellingCorcept Therapeutics shares fell below their 200-day moving average after insiders Roberto Vieira and Sean Maduck sold shares. Vieira sold 8,333 shares at $80.89, reducing his stake by 67.86%, while Maduck sold 13,159 shares at $82.25, cutting his holdings by 56.97%. The company's stock traded as low as $71.52.American Banking and Market NewsCorcept Therapeutics (NASDAQ:CORT) Stock Keeps “Overweight” Rating at Piper SandlerPiper Sandler reaffirmed an overweight rating on Corcept Therapeutics, raising its price target to $173 from $165. The company reported Q3 EPS of $1.01, beating estimates, and revenue of $340.47 million, up 64% year over year. It awaits a December 17 FDA decision on relacorilant.TradingViewPiper Sandler maintains Corcept Therapeutics at Overweight, raises price target to $173 from $165Piper Sandler maintained Corcept Therapeutics at Overweight and raised its price target to $173 from $165, a 4.8% increase. The target implies an upside of 111.2% from the Nov 3 close of $81.93.FinancialContent Business PageCORT Q3 2026 deep dive: rapid Lifyorli uptake and pipeline expansion shape outlookCorcept Therapeutics reported Q3 2026 revenue of $340.5 million, up 64% year-on-year, and adjusted EPS of $1.01, beating analyst estimates. The company reconfirmed full-year revenue guidance of $1.15 billion, citing accelerating Lifyorli uptake and endocrinology growth. Management expects the FDA decision on relacorilant for Cushing's syndrome by year-end.